Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Two People Awarded $9 Mln Each In Accutane Case

A New Jersey jury on Friday awarded $9 million each to two people who took the anti-acne drug Accutane, made by Hoffmann-La Roche (RHHBY.PK), and developed bowel disease. Accutane causes inflammatory bowel disease in some individuals.

This was the eighth Accutane case to go to trial in the U.S. To date, plaintiffs have won over $78 million in verdicts against Roche.

The trial lasted almost two months. The jury turned back the claims of two other clients as it found that although Roche failed to warn their prescribing physicians of the dangers of Accutane, they would have been prescribed and taken Accutane anyway.

Click here to receive FREE breaking news email alerts for Roche Holding AG and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Germany consumer confidence is set to improve further in August to the strongest level since December 2006 despite escalating geopolitical tensions in Israel and Ukraine, data from market research group GfK showed Friday. The forward-looking consumer sentiment index rose to 9 in August, while it was expected to remain unchanged at 8.9. This was the highest value recorded since December 2006. Amazon.com, Inc. said Thursday that its second quarter loss widened from last year, as operating expenses outpaced revenue growth amid heavy spending on new technology and contents. The company's quarterly loss per share was also wider than what analysts expected, but is quarterly sales came in line with analysts' forecast. The company also forecast an operating loss for the current quarter. After failing to sustain an initial upward move, stocks showed a lack of direction throughout much of the trading day on Thursday. The major averages eventually closed nearly unchanged, turning in a mixed performance for the second straight day.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.